EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape

Austin Frisch, Eric Martin, So Yeon Kim, Jonathan W Riess, Triparna Sen iD, Nagla Karim

The Oncologist · 04.06.2025 · 30 (6)

DOI: 10.1093/oncolo/oyaf153 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 30.06.2025. Verfasst von Austin Frisch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Inova Fairfax Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22042, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Mutation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is among one of the most common and deadliest malignancies worldwide. With this new era of precision medicine, oncogenic driver genes and immunotherapy have changed the way we classify and treat this disease. Among these genes, the Kirsten rat sarcoma virus (KRAS) gene is the most mutated in NSCLC and has been the focus of numerous clinical trials for targeted therapy over the past few years. Here, we present an in-depth literature review of past, present, and future KRAS mutated NSCLC treatment with KRAS inhibitor monotherapy and combinatorial approaches including immunotherapy. The molecular biology behind KRAS targeted therapy is discussed while highlighting the difficulties of KRAS inhibitor treatment, including resistance, and the next steps needed to overcome them.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins p21(ras)Lung NeoplasmsMutationHumansMolecular Targeted TherapyImmunotherapy

Stichwörter der Autor:innen

KRASNSCLCco-mutationresistancereview

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Inova Fairfax Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22042, United States.
  • Yale Cancer Center, Yale School of Medicine, New Haven, CT 06510, United States.
  • UC Davis Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, CA 95817, United States.
  • Department of Oncological Sciences, Icahn School of Medicine, Mount Sinai, New York, NY, 10029, United States.
  • Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, New York, NY 10029, United States.
  • Inova Schar Cancer Center, Inova Fairfax Hospital, Fairfax, VA 22042, United States.

ORCID-Profile: Triparna Sen

Zitieren

APA

Frisch, A., Martin, E., Kim, S. Y., Riess, J. W., Sen, T., & Karim, N. (2025). KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape. The Oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf153

Vancouver

Frisch A, Martin E, Kim SY, Riess JW, Sen T, Karim N. KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape. The Oncologist. 2025;30(6). doi:10.1093/oncolo/oyaf153

BibTeX
@article{Frisch2025,
  author = {Frisch, Austin and Martin, Eric and Kim, So Yeon and Riess, Jonathan W and Sen, Triparna and Karim, Nagla},
  title = {KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {6},
  doi = {10.1093/oncolo/oyaf153}
}
Kostenlos starten →